DelMar PHARMACEUTICALS

Vancouver, BC | Menlo Park, CA

Corporate Overview

Why Del Mar Pharma?

- ***Our lead drug is approved in overseas markets***
  - Opportunity for near-term revenue
- ***We know the drug works in our target indication***
  - Human clinical trial data from National Cancer Institute
- ***Our business model is unique & well validated***
  - Opportunity for significant near-term exit
- ***Our team has done this before***

Company Overview

- **Founded in 2010**
- **Rapidly developing & commercializing proven cancer therapies in orphan indications for patients failing modern biologic therapy**
- **VAL-083: First product opportunity**
  - U.S. IND filed Q4'10 : Refractory Glioblastoma Multiforme (post-Avastin failure)
  - Second orphan indication defined
  - Four new patents filed 2009/10
- **Significant near-term revenue potential**
  - International markets where drug is already approved
- **Defined pipeline expansion opportunities**
- **Experienced corporate & drug development team on board**
- **Seeking $5m in new capital**
  - Current bridge round of $1.5 million primarily to fund Phase II Human Clinical Trial

Glioblastoma Multiforme (GBM):
The Challenge, Opportunity & Competition

- *Glioblastoma Multiforme (GBM)*
  - Most common & most aggressive of primary brain tumors
  - 20,000 cases in N. America Annually
- *Current Treatment Paradigm*



Del Mar Pharma
Development Strategy

Front-line vs. Refractory: Regulatory Pathway

LONG DEVELOPMENT HORIZON

- New drug as standard of care in front-line GBM therapy – Registration Study Design
  - Randomized study vs. Standard of Care
  - >700 patients
  - $70 - $100 million
  - 6 – 7 years

-VS-

FAST-TRACK

- New drug as standard of care in salvage/ refractory situation – Registration Study Design
  - Single Arm Open Label
  - 80-100 patients
  - $8 - $10 million
  - 2 – 3 years
  - Potential fast-track & early approval based on "compassionate use"

The Del Mar Pharma Solution: VAL-083

Drug Profile

- Small-molecule chemotherapeutic
  - First-in-class chemistry
- Well characterized mechanism of action
  - Bi-functional akylating agent
  - Not cross resistant to current therapies
- Validated in more than 40 United States human clinical trials (National Cancer Institute) / Commercial product in China
  - Demonstrated efficacy in multiple tumor types
- Pharmacokinetics/Pharmacodynamics
  - Orally bioavailable
  - Rapidly crosses blood-brain-barrier with long half-life in CNS
  - Selective for brain tumors vs. intact white matter

VAL-083:

We know it works in GBM (Human Clinical Trials Data)



Benefit vs. Radiation

- Temodar™: 58 weeks
- VAL-083: 67 weeks

How Were Promising Drugs Overlooked?



Early 80s paradigm

- "Old" patents
- Value of orphan cancer indications not yet understood
- Major player (BMS) elected to focus on other primary candidates
- Invention of PCR ➔ Focus on "targeted" therapy
- HIV/AIDS

What has changed . . .

- Orphan drug act
- Targeted therapy reimbursement paradigm
- New IP strategies

Business Model:
Teaching Old Drugs New Tricks

Company / Origination	Product	Impact
cti *China*	**Trisenox™** *arsenic trioxide* *NSCLC - 706363*	✓ ***Approved for refractory APL (2000)*** ✓ ***Acquired (2005) $100m***
salmedix *East Germany*	**Treanda™** *Bendamustine* *NSCLC - 738783*	✓ ***Approved for refractory NHL (2008)*** ✓ ***Acquired (2005) - $200m*** ✓ ***Annual sales (2009) >$400m***
CHEMGENEX PHARMACEUTICALS *China*	**Omapro™** *Omacetaxine* *NSCLC - 141633*	✓ ***Approval pending for refractory CML*** ✓ ***Partnered (2009) - $125m*** ✓ ***Option to acquire control (2010) - >$200m***
DelMar PHARMACEUTICALS *China*	**VAL-083** NSCLC - undisclosed	✓ ***IND filed: refractory GBM*** ✓ ***Second target indication: AML*** ✓ ***Acquisition Opportunity: $$??***

VAL-083 Opportunity for Near Term Revenue

- In 2011 China will become third largest pharma market (behind U.S. and Japan)
  - ✓ 2010 China Pharma Sales = $40 billion
  - ✓ Chinese Pharma growth rate >25% vs. 5%-7% globally
- VAL-083 Approved in China for Leukemia & Solid Tumors (lung cancer)
  - ✓ … not promoted in Shanghai & Beijing
  - ✓ … not promoted for Lung Cancer
- Lung Cancer: 1 million cases per year in China by 2020
- Del Mar Pharma held ½ day exploratory symposium with leading Lung Cancer Physicians in Beijing Q42010

VAL-083: Development Strategy



Our Team

- **Capital Efficient / Low Burn:** Currently operates on a "virtual" basis
- **History of Success:** Collectively responsible for approval of more than 20 oncology drugs
- Founders & Advisors:
  - Jeffrey Bacha, BSc MBA – co-founder, President & CEO: Inimex / Inflazyme
  - Dennis Brown, PhD – co-founder, Chief Scientific Officer: Matrix / Chemgenex
  - Bill Garner, MD – co-founder: Urigen / Inverseon
  - Victor Levin, MD – Prof. Emeritus Neuro-Oncology MDACC
  - James Perry, MD – Chair, Canadian Brain Tumor Consortium

Key Team Member	Functional Expertise	Previous Corporate Affiliations
Richard Schwartz, MD	Clinical Affairs	Bayer / Axion
Sarath Kenekal, DVM, PhD	Clinical & pre-clinical pharmacology & toxicology	Matrix Pharma / Corixa / Salmedix / Chiron
Mike Li, MSc	Clinical manufacturing & analytical chemistry (CMC)	Matrix Pharma / Threshold Pharma / Horizon Pharma
Diann Nagami, PhD	Regulatory Affairs	Syntex Pharma / Pharmacyclics
Shawnya Michaels BSc	Discovery/Screening	Matrix Pharma / ChemGenex / Mountain View Pharma
Qi Xi, PhD	Business Development, China	>20 years chemistry & drug development experience in China

Financing

- ***Previous Fundraising***
  - ***$100,000 Seed Round (2010)***
  - ***~$500,000 founder investment to date***

  … plus >$50 million third-party investment from U.S. Natl. Cancer Inst. in VAL-083
- ***Multiple Opportunities for Early Revenue and Non-dilutive Financing***
- ***Current Offering***
  - ***Convertible Note Financing with 50% Warrant Coverage***
    - ***Fall-back conversion into common shares upon sale***
  - ***Seeking $1,500,000***
  - ***Use of Proceeds***
    - ***Clinical Development of VAL-083***
    - ***Patents & Intellectual Property Filings***
    - ***General Working Capital***

Del Mar Pharmaceuticals

Jeffrey Bacha, B.Sc., MBA – President & CEO

jbacha@delmarpharma.com

+1 604 317 7022

- ***Lead drug approved in overseas markets***
- ***Clinical evidence of efficacy in first target indication***
- ***Well validated, cost effective business model***
- ***Our team has done this before***

Corporate Headquarters:
Suite 400 - 1727 West Broadway
Vancouver, British Columbia
Canada V6J 4W6

Clinical Operations:
3475 Edison Way, Suite R
Menlo Park, California 94025
USA